ozgurdonmaz/E+ via Getty Images
H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop experienced by its stock over the past 30 days.
The selloff
